Vice President, Pharmaceutical Sciences in Global R&D
AbbVie
- PhD 1997, Purdue University
- AAPS Graduate Symposium Award in Drug Delivery and Pharmaceutical Technology for excellence in graduate research
- Received Abbott Laboratories President’s Award in 2004 for achieving cost savings of US$2,000,000 per year by improving manufacturing process of a powder for suspension commercial product
- Allergan R&D achievement award in 2009 for accelerating NDA filing of Latisse® as CMC team leader for the project. Product was launched 12 months ahead of planned date
- Allergan R&D achievement award in 2013 and 2019 for developing strategy & technical requirements for demonstrating equivalence of ophthalmic emulsions leading to revised FDA guidance(s)
- Over 25 US and WO patents granted in drug delivery, formulations and packaging design
- Contributed to development of: UbrelvyTM, Latisse®, Ozurdex®, Omnicef® 250mg/5mL, Aczone® Gel 7.5%, Rhofade®, SeysaraTM, Noctiva™, Restasis MultiDose®, Tripligan®, Ganfort® PF, Refresh® and Optive® consumer eye care products
Dr. Chetan Pujara is Vice President, Pharmaceutical Sciences in Global R&D at AbbVie in Irvine, California. His organization designs and develops dosage forms and drug-device combination products intended for clinical trials and commercialization primarily for Eye Care, Aesthetics and Neuroscience therapeutic areas. He also helps develop therapeutic area strategy as a member of the Eye Care therapeutic area strategy council and Aesthetics Pharma governance board.
Chetan has contributed to the development and approval of over 15 pharmaceutical products, drug-device combination products and CE-marked devices in his career since 1997 at Abbott Laboratories, Allergan and AbbVie. He is also an inventor on several patents in drug delivery, formulation development and packaging development.
Chetan supports the pharmaceutical sciences community by volunteering for non-profit organizations. He is a member of the USP <771> Ophthalmic Preparation Expert Panel and has previously served on the USP Dosage Forms Expert Committee. As an advisory board member, he helps sponsor industry-academia consortiums including Dane O. Kildsig Center for Pharmaceutical Processing Research. He is also an Adjunct Professor in the Department of Industrial and Physical Pharmacy at Purdue University and a Scientific Advisor to the Editors of J. Pharm Sci.
Chetan received his PhD in Pharmaceutics from Purdue University and BS degree in Pharmacy from Birla Institute of Technology and Science in Pilani, India.